Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE-STAR: Cranial Radiotherapy Plus Fulzerasib for KRAS G12C-Mutant NSCLC Brain Metastases
ChiCTR2600128388Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fulzerasib in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Shandong Cancer Hospital. Primary endpoint: Intracranial progression-free survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
fulzerasib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2600128388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128388.